| Efficacy and safety of everolimus in treatment of advanced angiosarcoma |
| Received:January 09, 2019 Revised:April 17, 2019 Click here to download the full text |
| Citation of this paper:李智勇， 张秀萍， 张世龙， 许建芳， 王志明， 周宇红.Efficacy and safety of everolimus in treatment of advanced angiosarcoma[J].Chinese Journal of Clinical Medicine,2019,26(3):387-390 |
| Hits: 1717 |
| Download times: 952 |
|
| Abstract:Objective：To investigate the efficacy and safety of mTOR inhibitor everolimus in the treatment of advanced angiosarcoma. Methods：Clinical data of 5 patients with advanced angiosarcoma initially treated with everolimus from November 2013 to September 2018 were collected to observe the efficacy and adverse reactions. Results：The symptoms of 4 patients with advanced angiosarcoma were relieved and the lesions narrowed within a few days after the treatment of everolimus. One patient with advanced angiosarcoma who was resistant to apatinib continued to progress. The main adverse effects of everolimus were oral ulcers, of which 2 cases were grade 2 and 3 cases were grade 1. Conclusions：Everolimus is effective in the treatment of advanced angiosarcoma with rapid onset of action and controllable adverse effects. |
| keywords:angiosarcoma everolimus initial treatment adverse effects |
| HTML View Full Text View/Add Comment Download reader |